The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma
Open accessAbstract
Blocking autophagy with hydroxychloroquine (HCQ) augments cell death associated with alkylating chemotherapy in preclinical models. This phase I study evaluated the maximum tolerated dose (MTD), safety, preliminary activity, pharmacokinetics, and pharmacodynamics of HCQ in combination with dose-intense temozolomide (TMZ) in patients with advanced solid malignancies. Forty patients (73% metastatic melanoma) were treated with oral HCQ 200 to 1200 mg daily with dose-intense oral TMZ 150 mg/m (2) daily for 7/14 d. This combination was well tolerated with no recurrent dose-limiting toxicities observed. An MTD was not reached for HCQ and the recommended phase II dose was HCQ 600 mg twice daily combined with dose-intense TMZ. Common toxicities included grade 2 fatigue (55%), anorexia (28%), nausea (48%), constipation (20%), and diarrhea (20%). Partial responses and stable disease were observed in 3/22 (14%) and 6/22 (27%) patients with metastatic melanoma. In the final dose cohort 2/6 patients with refractory BRAF wild-type melanoma had a near complete response, and prolonged stable disease, respectively. A significant accumulation in autophagic vacuoles (AV) in peripheral blood mononuclear cells was observed in response to combined therapy. Population pharmacokinetics (PK) modeling, individual PK simulations, and PK-pharmacodynamics (PD) analysis identified a threshold HCQ peak concentration that predicts therapy-associated AV accumulation. This study indicates that the combination of high-dose HCQ and dose-intense TMZ is safe and tolerable, and is associated with autophagy modulation in patients. Prolonged stable disease and responses suggest antitumor activity in melanoma patients, warranting further studies of this combination, or combinations of more potent autophagy inhibitors and chemotherapy in melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Pancreatic cancers require autophagy for tumor growth
Yang, S., Wang, X., Contino, G., Liesa, M., Sahin, E., Ying, H., Bause, A., Li, Y., Stommel, J. M., Dell'Antonio, G., et al. (2011) · Genes & Development · doi:10.1101/gad.2016111 · Cited by 1,498
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
Guo, J. Y., Chen, H.-Y., Mathew, R., Fan, J., Strohecker, A. M., Karsli-Uzunbas, G., Kamphorst, J. J., Chen, G., Lemons, J. M. S., Karantza, V., et al. (2011) · Genes & Development · doi:10.1101/gad.2016311 · Cited by 1,323
Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
Amaravadi, R. K., Yu, D., Lum, J. J., Bui, T., Christophorou, M. A., Evan, G. I., Thomas-Tikhonenko, A., & Thompson, C. B. (2007) · Journal of Clinical Investigation · doi:10.1172/jci28833 · Cited by 1,137
Self-citationRole of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y., & Kondo, S. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401359 · Cited by 986
Principles and Current Strategies for Targeting Autophagy for Cancer Treatment
Amaravadi, R. K., Lippincott-Schwartz, J., Yin, X.-M., Weiss, W. A., Takebe, N., Timmer, W., DiPaola, R. S., Lotze, M. T., & White, E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2634 · Cited by 897
Self-citationGuo, J. Y., Karsli-Uzunbas, G., Mathew, R., Aisner, S. C., Kamphorst, J. J., Strohecker, A. M., Chen, G., Price, S., Lu, W., Teng, X., et al. (2013) · Genes & Development · doi:10.1101/gad.219642.113 · Cited by 589
Rosenfeld, M. R., Ye, X., Supko, J. G., Desideri, S., Grossman, S. A., Brem, S., Mikkelson, T., Wang, D., Chang, Y. C., Hu, J., et al. (2014) · Autophagy · doi:10.4161/auto.28984 · Cited by 515
Self-citationAutophagy Sustains Mitochondrial Glutamine Metabolism and Growth of Braf V600E–Driven Lung Tumors
Strohecker, A. M., Guo, J. Y., Karsli-Uzunbas, G., Price, S. M., Chen, G. J., Mathew, R., McMahon, M., & White, E. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0397 · Cited by 435
Rangwala, R., Chang, Y. C., Hu, J., Algazy, K. M., Evans, T. L., Fecher, L. A., Schuchter, L. M., Torigian, D. A., Panosian, J. T., Troxel, A. B., et al. (2014) · Autophagy · doi:10.4161/auto.29119 · Cited by 424
Self-citationVogl, D. T., Stadtmauer, E. A., Tan, K.-S., Heitjan, D. F., Davis, L. E., Pontiggia, L., Rangwala, R., Piao, S., Chang, Y. C., Scott, E. C., et al. (2014) · Autophagy · doi:10.4161/auto.29264 · Cited by 368
Self-citationKatayama, M., Kawaguchi, T., Berger, M. S., & Pieper, R. O. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402030 · Cited by 353
Mahalingam, D., Mita, M., Sarantopoulos, J., Wood, L., Amaravadi, R. K., Davis, L. E., Mita, A. C., Curiel, T. J., Espitia, C. M., Nawrocki, S. T., et al. (2014) · Autophagy · doi:10.4161/auto.29231 · Cited by 285
Self-citationHydroxychloroquine concentration–response relationships in patients with rheumatoid arthritis
Munster, T., Gibbs, J. P., Shen, D., Baethge, B. A., Botstein, G. R., Caldwell, J., Dietz, F., Ettlinger, R., Golden, H. E., Lindsley, H., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10307 · Cited by 249
Ma, X.-H., Piao, S., Wang, D., Mcafee, Q. W., Nathanson, K. L., Lum, J. J., Li, L. Z., & Amaravadi, R. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2372 · Cited by 234
Self-citationPatel, P. M., Suciu, S., Mortier, L., Kruit, W. H., Robert, C., Schadendorf, D., Trefzer, U., Punt, C. J. A., Dummer, R., Davidson, N., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.04.030 · Cited by 211
Xu, N., Zhang, J., Shen, C., Luo, Y., Xia, L., Xue, F., & Xia, Q. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.06.048 · Cited by 188
Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials
Lin, Y. (2001) · Biostatistics · doi:10.1093/biostatistics/2.2.203 · Cited by 171
Lim, H.-S., Im, J.-S., Cho, J.-Y., Bae, K.-S., Klein, T. A., Yeom, J.-S., Kim, T.-S., Choi, J.-S., Jang, I.-J., & Park, J.-W. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00339-08 · Cited by 163
Barnard, R. A., Wittenburg, L. A., Amaravadi, R. K., Gustafson, D. L., Thorburn, A., & Thamm, D. H. (2014) · Autophagy · doi:10.4161/auto.29165 · Cited by 162
Self-citationAmaravadi, R. K., Schuchter, L. M., McDermott, D. F., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2074 · Cited by 117
Self-citationTrudeau, M., Crump, M., Charpentier, D., Yelle, L., Bordeleau, L. J., Matthews, S. W., & Eisenhauer, E. A. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl056 · Cited by 113
Siena, S., Crinò, L., Danova, M., Prete, S. D., Cascinu, S., Salvagni, S., Schiavetto, I., Vitali, M., & Bajetta, E. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp343 · Cited by 102
Dose‐dense temozolomide regimens
Neyns, B., Tosoni, A., Hwu, W., & Reardon, D. A. (2010) · Cancer · doi:10.1002/cncr.25035 · Cited by 98
Targeting Autophagy Augments In Vitro and In Vivo Antimyeloma Activity of DNA-Damaging Chemotherapy
Pan, Y., Gao, Y., Chen, L., Gao, G., Dong, H., Yang, Y., Dong, B., & Chen, X. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0890 · Cited by 87
Temozolomide and unusual indications: Review of literature
Tatar, Z., Thivat, É., Planchat, E., Gimbergues, P., Gadéa, É., Abrial, C., & Durando, X. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.06.002 · Cited by 83
Induction of autophagy in temozolomide treated malignant gliomas
Natsumeda, M., Aoki, H., Miyahara, H., Yajima, N., Uzuka, T., Toyoshima, Y., Kakita, A., Takahashi, H., & Fujii, Y. (2011) · Neuropathology · doi:10.1111/j.1440-1789.2010.01197.x · Cited by 61
Effect of temozolomide on the U-118 glioma cell line
do Carmo, A., Carvalheiro, H., Crespo, I., Nunes‐Correia, I., & Lopes, M. C. (2011) · Oncology Letters · doi:10.3892/ol.2011.406 · Cited by 56
Cited by
Levy, J. M. M., Towers, C. G., & Thorburn, A. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.53 · Cited by 2,526
Mechanisms of action of hydroxychloroquine and chloroquine:implications for rheumatology
Schrezenmeier, E., & Dörner, T. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0372-x · Cited by 1,468
Autophagy in malignant transformation and cancer progression
Galluzzi, L., Pietrocola, F., Bravo‐San Pedro, J. M., Amaravadi, R. K., Baehrecke, E. H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D. A., Karantza, V., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490784 · Cited by 1,182
Self-citationBorba, M. G. S., Val, F. F. A., Sampaio, V. S., Alexandre, M. A. A., Melo, G. C., Brito, M., Mourão, M. P. G., Brito-Sousa, J. D., Baía-da-Silva, D., Guerra, M. V. F., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.8857 · Cited by 1,038
Targeting Autophagy in Cancer: Recent Advances and Future Directions
Amaravadi, R. K., Kimmelman, A. C., & Debnath, J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0292 · Cited by 928
Self-citation
Metadata
- Authors
- Rangwala, R., Leone, R., Chang, Y. C., Fecher, L. A., Schuchter, L. M., Kramer, A., Tan, K.-S., Heitjan, D. F., Rodgers, G., Gallagher, M., Piao, S., Troxel, A. B., Evans, T. L., DeMichele, A. M., Nathanson, K. L., O’Dwyer, P. J., Kaiser, J., Pontiggia, L., Davis, L. E., & Amaravadi, R. K.
- Venue
- Autophagy
- Publisher
- Informa UK Limited
- Published
- 2014-05-20
- Volume
- 10
- Issue
- 8
- Pages
- 1369-1379
- ISSN
- 1554-8627 (ISSN-L)
- 1554-8635
- OpenAlex
- W2055510039
- Cited by
- 367
- References
- 30
- FWCI
- 27.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.